search
Back to results

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (TITAN-TCC)

Primary Purpose

Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Nivolumab/Ipilimumab
Sponsored by
AIO-Studien-gGmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Transitional Cell Carcinoma focused on measuring tailored immuno therapy, Nivolumab, Ipilimumab, boost

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed Written Informed Consent

    • Subjects or legally acceptable representatives must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care.
    • Subjects or legally acceptable representatives must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study.
  • Target Population

    • Histological evidence of metastatic or surgically unresectable transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis. Minor histologic variants of transitional cell carcinoma (e.g. squamous cell, comprising <50 % of the tumor overall) are acceptable.
    • Subjects must have advanced or surgically unresectable TCC (cT4b, any N or any T, N2-N3 or any M1) or having progressed during or after platinum-based first line therapy and up to 1 further treatment line (2nd and 3rd line cohort). Subjects, who have received neoadjuvant or adjuvant cisplatin based chemotherapy are eligible and considered first line provided that progression has occurred >12 months from last therapy [for chemoradiation and adjuvant treatment] or >12 months from last surgery [for neoadjuvant treatment]; in all other patients who received cisplatin based neoadjuvant and/or adjuvant chemotherapy and progression within 12 months this will be considered one line of therapy. [*Update January 2020:First-line cohort has been stopped since 31-Jan-2019 and wont be restarted]
    • KPS of at least 70% (See Appendix 1)
    • Measurable disease as per RECIST v1.1 (See Appendix 2)
    • Formalin-fixed paraffin embedded tumor tissue obtained within 2 years prior to screening must be available and received by the central pathology (tumor block is preferred, alternatively 15 unstained slides). Note that:

      1. Fine Needle Aspiration [FNA] and bone metastases samples (without soft tissue component) are not acceptable for submission).
      2. Tumor lesions used for newly acquired biopsies should not be target lesions, unless there are no other lesions.
  • Age and Reproductive Status

    • Males and Females, ≥ 18 years of age
    • Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug.
    • Women must not be breastfeeding
    • Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for a period of 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo five half lives. The terminal half lives of nivolumab and ipilimumab are up to 25 days and 18 days, respectively. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.
    • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo five half lives. The terminal half lives of nivolumab and ipilimumab are up to 25 days and 18 days, respectively. Males who receive nivolumab combined with ipilimumab who are sexually active with WOCBP must continue contraception for 31 weeks (90 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.

      • Comment: Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, WOCBP must still undergo pregnancy testing as described in this section.

Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly.

At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective as listed below:

HIGHLY EFFECTIVE METHODS OF CONTRACEPTION

  • Male condoms with spermicide
  • Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectables, implants and intrauterine devices (IUDs) such as Mirena® by WOCBP subject or male subject's WOCBP partner. Female partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception since they will not be receiving study drug
  • Nonhormonal IUDs, such as ParaGard®
  • Tubal ligation
  • Vasectomy
  • Complete Abstinence*

    • *Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. Subjects who choose complete abstinence are not required to use a second method of contraception, but female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence.

LESS EFFECTIVE METHODS OF CONTRACEPTION

  • Diaphragm with spermicide
  • Cervical cap with spermicide
  • Vaginal sponge
  • Male Condom without spermicide
  • Progestin only pills by WOCBP subject or male subject's WOCBP partner
  • Female Condom*.

    • * A male and female condom must not be used together

Exclusion Criteria:

  • Target Disease Exceptions

    • Any history of or current CNS metastases. Baseline imaging of the brain by MRI (preferred) or CT scan is required within 28 days prior to registration in 2nd/3rd line patients only.
  • Medical History and Concurrent Diseases

    • Prior systemic treatment with more than two different chemotherapy regimen (Sequential chemotherapy as a planned sequence to optimize response will count as 1 regimen)
    • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti CTLA 4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
    • Any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (> 10 mg daily prednisone equivalent) or immunosuppressive medications except for syndromes which would not be expected to recur in the absence of an external trigger. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll.
    • Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
    • Prior malignancy active within the previous 3 years except for

      1. locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
      2. Patients in active surveillance for prostate cancer
    • Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
    • Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection.
    • Known medical condition (eg, a condition associated with diarrhea or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.
    • Major surgery (eg, nephrectomy) less than 28 days prior to the first dose of study drug.
    • Anti-cancer therapy less than 28 days prior to the first dose of study drug or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug.
    • Presence of any toxicities attributed to prior anti-cancer therapy other than neuropathy, alopecia and fatigue, that have not resolved to Grade 1 (NCI CTCAE v4) or baseline before administration of study drug.
  • Physical and Laboratory Test Findings

    • Any of the following laboratory test findings:

      1. WBC < 2,000/mm^3
      2. Neutrophils < 1,500/mm^3
      3. Platelets < 100,000/mm^3
      4. AST or ALT > 3 x ULN (> 5 x ULN if liver metastases are present)
      5. Total Bilirubin > 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
      6. Serum creatinine > 1.5 x upper limit of normal (ULN) or creatinine clearance < 40 mL/min (measured or calculated by Cockroft-Gault formula):

        • Female CrCl = [(140 - age in years) x weight in kg x 0.85] / [72 x serum creatinine in mg/dL]
        • Male CrCl = [(140 - age in years) x weight in kg x 1.00] / [72 x serum creatinine in mg/dL]
  • Allergies and Adverse Drug Reaction

    • History of severe hypersensitivity reaction to any monoclonal antibody or any constituent of the products.
  • Other Exclusion Criteria

    • Prisoners or subjects who are involuntarily incarcerated
    • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
    • Participation in another clinical intervention trial 30 days prior to registration

Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.

Subject Re-enrollment: This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (ie, subject has not been registered / has not been treated). If re-enrolled, the subject must be re-consented.

Sites / Locations

  • Univ. Klinik für Innere Medizin
  • Ordensklinikum Linz - KH Barmherzige Schwestern
  • Universitätsklinikum Salzburg
  • Landesklinikum Wiener Neustadt
  • KH der Barmherzigen Brüder Wien
  • Universitätsklinikum Jena und Poliklinik für Urologie
  • Uniklinik der RWTH Aachen
  • Vivantes Klinikum Neukölln
  • Uniklinik C.-G.-Dresden
  • Universitätsklinikum Düsseldorf
  • Helios Klinikum Erfurt
  • Universitätsklinikum Erlangen
  • Chirurgische Universitätsklinik Freiburg
  • Überörtliche Gemeinschaftspraxis für Urologie GbR
  • Greifswald Universitätsklinikum
  • Universitätsklinikum Heidelberg Chirurgische Klinik Klinik für Urologie
  • Marien Hospital
  • Urologie Herzberg
  • Studienzentrum Bayenthal
  • Universitätsklinikum Magdeburg
  • UKGM Marburg
  • Klinikum der Universität München - Großhadern
  • Universitätsklinikum Münster
  • Universtätsmedizin Rostock
  • Universitätsklinikum Ulm
  • Kliniken Nordoberpfalz AG, Klinikum Weiden
  • Urologie Praxis am Wasserturm

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Nivolumab/Ipilimumab

Arm Description

Induction: Mono-Therapy with Nivolumab If CR/PR: Nivolumab Maintenance Mono-Therapy If SD/PD: Nivolumab/Ipilimumab "Boost 1+2"-Combination Therapy If CR/PR: Nivolumab Maintenance Mono-Therapy If SD/PD: Nivolumab/Ipilimumab "Boost 3+4"-Combination Therapy If CR/PR/SD: Nivolumab Maintenance Mono-Therapy

Outcomes

Primary Outcome Measures

Objective Response Rate (ORR)
The primary objective will be measured by the primary endpoint of ORR (based on investigator assessments) among all treated subjects, first line subjects and second line subjects. It is defined as the number of subjects with a best overall response of CR or PR divided by the number of all treated subjects, first line subjects or second line subjects. Best overall response is defined as the best response designation, as determined by investigator, recorded between the date of first dose and the date of objectively documented immunotherapy resistance per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.

Secondary Outcome Measures

Remission Rates (RR)
Remission Rates (RR) during TITAN treatment: CR/PR
Time to Immunotherapy Resistance (TIR)
Time to Immunotherapy Resistance (TIR) will be used as a surrogate parameter of progression free survival using a tailored Immunotherapy regimen with "boost" cycles upon initial progression.
Time to Response (TTR)
TTR is defined either as the time from first dosing date or initiation of nivolumab/ipilimumab "boost" cycles to the date of the first confirmed response thereafter, as assessed by the IRC. Hence, TTR may be recorded several times per patient.
Duration of Response (DOR)
DOR is defined as the time from first confirmed response (CR or PR) to the date of the documented progressive disease as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. DOR may be recorded multiple times per patient.
Progression free survival (PFS)
PFS is defined as the time from first dosing date to the date of the first documented tumor progression based on investigator assessments (per RECIST 1.1), or death due to any cause. Clinical deterioration in the absence of unequivocal evidence of progression (per RECIST 1.1) is not considered progression for purposes of determining PFS.
Overall survival (OS)
OS is defined as the time from first dosing date to the date of death. A subject who has not died will be censored at last known date alive.
Safety - Incidence of adverse events, serious adverse events, deaths and laboratory abnormalities
Safety and tolerability objective will be measured by the incidence of adverse events, serious adverse events, deaths and laboratory abnormalities. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
EORTC QLQ-C30
Questionaires
EQ-5D
Questionaires
EQ-5D VAS
Visual analogue scale

Full Information

First Posted
July 4, 2017
Last Updated
November 2, 2021
Sponsor
AIO-Studien-gGmbH
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT03219775
Brief Title
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
Acronym
TITAN-TCC
Official Title
A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 6, 2017 (Actual)
Primary Completion Date
September 16, 2021 (Actual)
Study Completion Date
February 18, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AIO-Studien-gGmbH
Collaborators
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
TITAN-TCC (0416-ASG) is a Phase 2, open-label study of nivolumab (BMS-936558) monotherapy with additional nivolumab/ipilimumab "boost" cycles in previously untreated* and platinum-based pretreated, 2nd and 3rd line, advanced or metastatic transitional cell carcinoma subjects. Nivolumab is a fully human PD-1 antibody which blocks the respective immune checkpoint in a ligand (PD-L1/PD-L2) independent manner. [*Update from Jan-2020: First-line cohort was stopped and the inclusion of these patients was terminated]
Detailed Description
This is a Phase 2, single arm study of a tailored immunotherapy approach with nivolumab in adult (≥ 18 years) subjects with previously untreated (1st line)* or pretreated (2nd and 3rd line), surgically unresectable or metastatic TCC (further designated "advanced TCC"). The study targets to recruit 130 untreated (1st line) and 120 pretreated (2nd / 3rd line) patients, respectively. Tumor tissue obtained at least 2 years prior to screening must be available for a central pathology assessment. Subjects must have advanced (not amenable to curative surgery or radiation) or metastatic TCC, and must not have received more than two prior platinum-based chemotherapies for the treatment of advanced TCC. [*Update from Jan-2020: First-line cohort was stopped and the inclusion of these patients was terminated. According protocol v.5.0 80 2nd/3rd-line patients need to be included]

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer
Keywords
tailored immuno therapy, Nivolumab, Ipilimumab, boost

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
169 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nivolumab/Ipilimumab
Arm Type
Experimental
Arm Description
Induction: Mono-Therapy with Nivolumab If CR/PR: Nivolumab Maintenance Mono-Therapy If SD/PD: Nivolumab/Ipilimumab "Boost 1+2"-Combination Therapy If CR/PR: Nivolumab Maintenance Mono-Therapy If SD/PD: Nivolumab/Ipilimumab "Boost 3+4"-Combination Therapy If CR/PR/SD: Nivolumab Maintenance Mono-Therapy
Intervention Type
Biological
Intervention Name(s)
Nivolumab/Ipilimumab
Other Intervention Name(s)
Opdivo/Yervoy
Intervention Description
Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4) If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W) If SD/PD: Nivolumab/Ipilimumab "Boost 1+2"-Combination Therapy (Nivo1 mg/kg i.V. and Ipi3 mg/kg i.V. / Q3W x 2)* If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W) If SD/PD: Nivolumab/Ipilimumab "Boost 3+4"-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2) If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W) since June 5, 2019, the treatment in all four "boost" cycles (1+2) and (3+4) is performed with nivolumab 1 mg/kg + ipilimumab 3 mg/kg (NIVO1/IPI3)
Primary Outcome Measure Information:
Title
Objective Response Rate (ORR)
Description
The primary objective will be measured by the primary endpoint of ORR (based on investigator assessments) among all treated subjects, first line subjects and second line subjects. It is defined as the number of subjects with a best overall response of CR or PR divided by the number of all treated subjects, first line subjects or second line subjects. Best overall response is defined as the best response designation, as determined by investigator, recorded between the date of first dose and the date of objectively documented immunotherapy resistance per RECIST v1.1 or the date of subsequent therapy, whichever occurs first.
Time Frame
max. months
Secondary Outcome Measure Information:
Title
Remission Rates (RR)
Description
Remission Rates (RR) during TITAN treatment: CR/PR
Time Frame
max. 68 months
Title
Time to Immunotherapy Resistance (TIR)
Description
Time to Immunotherapy Resistance (TIR) will be used as a surrogate parameter of progression free survival using a tailored Immunotherapy regimen with "boost" cycles upon initial progression.
Time Frame
max. 68 months
Title
Time to Response (TTR)
Description
TTR is defined either as the time from first dosing date or initiation of nivolumab/ipilimumab "boost" cycles to the date of the first confirmed response thereafter, as assessed by the IRC. Hence, TTR may be recorded several times per patient.
Time Frame
max. 68 months
Title
Duration of Response (DOR)
Description
DOR is defined as the time from first confirmed response (CR or PR) to the date of the documented progressive disease as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. DOR may be recorded multiple times per patient.
Time Frame
max. 68 months
Title
Progression free survival (PFS)
Description
PFS is defined as the time from first dosing date to the date of the first documented tumor progression based on investigator assessments (per RECIST 1.1), or death due to any cause. Clinical deterioration in the absence of unequivocal evidence of progression (per RECIST 1.1) is not considered progression for purposes of determining PFS.
Time Frame
max. 68 months
Title
Overall survival (OS)
Description
OS is defined as the time from first dosing date to the date of death. A subject who has not died will be censored at last known date alive.
Time Frame
max. 68 months
Title
Safety - Incidence of adverse events, serious adverse events, deaths and laboratory abnormalities
Description
Safety and tolerability objective will be measured by the incidence of adverse events, serious adverse events, deaths and laboratory abnormalities. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Time Frame
max. 68 months
Title
EORTC QLQ-C30
Description
Questionaires
Time Frame
max. 68 months
Title
EQ-5D
Description
Questionaires
Time Frame
max. 68 months
Title
EQ-5D VAS
Description
Visual analogue scale
Time Frame
max. 68 months
Other Pre-specified Outcome Measures:
Title
Immune monitoring (Exploratory Endpoint)
Description
Parameters will be analysed with regard to the prediction of response as well as immune related adverse events.
Time Frame
max. 68 months
Title
PD-L1 and PD-L2
Description
the expression of PD-L1 and PD-L2 in tumor tissues of mTCC patients will be correlated with efficacy parameters.
Time Frame
max. 68 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed Written Informed Consent Subjects or legally acceptable representatives must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care. Subjects or legally acceptable representatives must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study. Target Population Histological evidence of metastatic or surgically unresectable transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis. Minor histologic variants of transitional cell carcinoma (e.g. squamous cell, comprising <50 % of the tumor overall) are acceptable. Subjects must have advanced or surgically unresectable TCC (cT4b, any N or any T, N2-N3 or any M1) or having progressed during or after platinum-based first line therapy and up to 1 further treatment line (2nd and 3rd line cohort). Subjects, who have received neoadjuvant or adjuvant cisplatin based chemotherapy are eligible and considered first line provided that progression has occurred >12 months from last therapy [for chemoradiation and adjuvant treatment] or >12 months from last surgery [for neoadjuvant treatment]; in all other patients who received cisplatin based neoadjuvant and/or adjuvant chemotherapy and progression within 12 months this will be considered one line of therapy. [*Update January 2020:First-line cohort has been stopped since 31-Jan-2019 and wont be restarted] KPS of at least 70% (See Appendix 1) Measurable disease as per RECIST v1.1 (See Appendix 2) Formalin-fixed paraffin embedded tumor tissue obtained within 2 years prior to screening must be available and received by the central pathology (tumor block is preferred, alternatively 15 unstained slides). Note that: Fine Needle Aspiration [FNA] and bone metastases samples (without soft tissue component) are not acceptable for submission). Tumor lesions used for newly acquired biopsies should not be target lesions, unless there are no other lesions. Age and Reproductive Status Males and Females, ≥ 18 years of age Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug. Women must not be breastfeeding Women of childbearing potential (WOCBP) must agree to follow instructions for method(s) of contraception for a period of 30 days (duration of ovulatory cycle) plus the time required for the investigational drug to undergo five half lives. The terminal half lives of nivolumab and ipilimumab are up to 25 days and 18 days, respectively. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) plus the time required for the investigational drug to undergo five half lives. The terminal half lives of nivolumab and ipilimumab are up to 25 days and 18 days, respectively. Males who receive nivolumab combined with ipilimumab who are sexually active with WOCBP must continue contraception for 31 weeks (90 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug. Comment: Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However, WOCBP must still undergo pregnancy testing as described in this section. Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy Investigators shall advise WOCBP and male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly. At a minimum, subjects must agree to the use of two methods of contraception, with one method being highly effective and the other method being either highly effective or less effective as listed below: HIGHLY EFFECTIVE METHODS OF CONTRACEPTION Male condoms with spermicide Hormonal methods of contraception including combined oral contraceptive pills, vaginal ring, injectables, implants and intrauterine devices (IUDs) such as Mirena® by WOCBP subject or male subject's WOCBP partner. Female partners of male subjects participating in the study may use hormone based contraceptives as one of the acceptable methods of contraception since they will not be receiving study drug Nonhormonal IUDs, such as ParaGard® Tubal ligation Vasectomy Complete Abstinence* *Complete abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. Subjects who choose complete abstinence are not required to use a second method of contraception, but female subjects must continue to have pregnancy tests. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence. LESS EFFECTIVE METHODS OF CONTRACEPTION Diaphragm with spermicide Cervical cap with spermicide Vaginal sponge Male Condom without spermicide Progestin only pills by WOCBP subject or male subject's WOCBP partner Female Condom*. * A male and female condom must not be used together Exclusion Criteria: Target Disease Exceptions Any history of or current CNS metastases. Baseline imaging of the brain by MRI (preferred) or CT scan is required within 28 days prior to registration in 2nd/3rd line patients only. Medical History and Concurrent Diseases Prior systemic treatment with more than two different chemotherapy regimen (Sequential chemotherapy as a planned sequence to optimize response will count as 1 regimen) Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti CTLA 4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. Any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (> 10 mg daily prednisone equivalent) or immunosuppressive medications except for syndromes which would not be expected to recur in the absence of an external trigger. Subjects with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll. Any condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast. Patients in active surveillance for prostate cancer Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS). Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection. Known medical condition (eg, a condition associated with diarrhea or acute diverticulitis) that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results. Major surgery (eg, nephrectomy) less than 28 days prior to the first dose of study drug. Anti-cancer therapy less than 28 days prior to the first dose of study drug or palliative, focal radiation therapy less than 14 days prior to the first dose of study drug. Presence of any toxicities attributed to prior anti-cancer therapy other than neuropathy, alopecia and fatigue, that have not resolved to Grade 1 (NCI CTCAE v4) or baseline before administration of study drug. Physical and Laboratory Test Findings Any of the following laboratory test findings: WBC < 2,000/mm^3 Neutrophils < 1,500/mm^3 Platelets < 100,000/mm^3 AST or ALT > 3 x ULN (> 5 x ULN if liver metastases are present) Total Bilirubin > 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) Serum creatinine > 1.5 x upper limit of normal (ULN) or creatinine clearance < 40 mL/min (measured or calculated by Cockroft-Gault formula): Female CrCl = [(140 - age in years) x weight in kg x 0.85] / [72 x serum creatinine in mg/dL] Male CrCl = [(140 - age in years) x weight in kg x 1.00] / [72 x serum creatinine in mg/dL] Allergies and Adverse Drug Reaction History of severe hypersensitivity reaction to any monoclonal antibody or any constituent of the products. Other Exclusion Criteria Prisoners or subjects who are involuntarily incarcerated Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness Participation in another clinical intervention trial 30 days prior to registration Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria. Subject Re-enrollment: This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (ie, subject has not been registered / has not been treated). If re-enrolled, the subject must be re-consented.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc-Oliver Grimm, Prof. Dr.
Organizational Affiliation
Universitätsklinikum Jena
Official's Role
Principal Investigator
Facility Information:
Facility Name
Univ. Klinik für Innere Medizin
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Ordensklinikum Linz - KH Barmherzige Schwestern
City
Linz
ZIP/Postal Code
4010
Country
Austria
Facility Name
Universitätsklinikum Salzburg
City
Salzburg
ZIP/Postal Code
5020
Country
Austria
Facility Name
Landesklinikum Wiener Neustadt
City
Wiener Neustadt
ZIP/Postal Code
2700
Country
Austria
Facility Name
KH der Barmherzigen Brüder Wien
City
Wien
ZIP/Postal Code
1020
Country
Austria
Facility Name
Universitätsklinikum Jena und Poliklinik für Urologie
City
Jena
State/Province
Thüringen
ZIP/Postal Code
07747
Country
Germany
Facility Name
Uniklinik der RWTH Aachen
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Facility Name
Vivantes Klinikum Neukölln
City
Berlin
ZIP/Postal Code
12351
Country
Germany
Facility Name
Uniklinik C.-G.-Dresden
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Universitätsklinikum Düsseldorf
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
Facility Name
Helios Klinikum Erfurt
City
Erfurt
ZIP/Postal Code
99089
Country
Germany
Facility Name
Universitätsklinikum Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Facility Name
Chirurgische Universitätsklinik Freiburg
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Überörtliche Gemeinschaftspraxis für Urologie GbR
City
Fürth
ZIP/Postal Code
90763
Country
Germany
Facility Name
Greifswald Universitätsklinikum
City
Greifswald
ZIP/Postal Code
17475
Country
Germany
Facility Name
Universitätsklinikum Heidelberg Chirurgische Klinik Klinik für Urologie
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Marien Hospital
City
Herne
ZIP/Postal Code
44625
Country
Germany
Facility Name
Urologie Herzberg
City
Herzberg am Harz
ZIP/Postal Code
37412
Country
Germany
Facility Name
Studienzentrum Bayenthal
City
Köln
ZIP/Postal Code
50968
Country
Germany
Facility Name
Universitätsklinikum Magdeburg
City
Magdeburg
ZIP/Postal Code
39120
Country
Germany
Facility Name
UKGM Marburg
City
Marburg an der Lahn
ZIP/Postal Code
35033
Country
Germany
Facility Name
Klinikum der Universität München - Großhadern
City
München
ZIP/Postal Code
81377
Country
Germany
Facility Name
Universitätsklinikum Münster
City
Münster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Universtätsmedizin Rostock
City
Rostock
ZIP/Postal Code
18057
Country
Germany
Facility Name
Universitätsklinikum Ulm
City
Ulm
ZIP/Postal Code
89075
Country
Germany
Facility Name
Kliniken Nordoberpfalz AG, Klinikum Weiden
City
Weiden
ZIP/Postal Code
92637
Country
Germany
Facility Name
Urologie Praxis am Wasserturm
City
Würselen
ZIP/Postal Code
52146
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
35275706
Citation
Grimm MO, Schmitz-Drager BJ, Zimmermann U, Grun CB, Baretton GB, Schmitz M, Foller S, Leucht K, Schostak M, Zengerling F, Schumacher U, Loidl W, Meran J. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma. J Clin Oncol. 2022 Jul 1;40(19):2128-2137. doi: 10.1200/JCO.21.02631. Epub 2022 Mar 11.
Results Reference
derived

Learn more about this trial

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

We'll reach out to this number within 24 hrs